Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria

A legfontosabb adatok

Ki végzi
Novartis Pharmaceuticals
Hol
Burkina Faso, Elefántcsontpart, Gabon, Ghána, Kenya, Kongó – Kinshasa, Mali, Niger, Ruanda, Tanzánia, Uganda és Zambia32 helyszín, 12 országbanVálassz országot a helyszínekhez
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
1720 fő vett részt
Kezdés
2024. márc. 7.
Befejezés
2025. nov. 25.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • KLU156
  • Coartem
A regiszteradat frissítve
2026. november 4.

Ki vehet részt

Életkor
2 hónap – 100 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 17 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female patients ≥ 10 kg of body weight
  • Microscopically confirmed diagnosis of uncomplicated P. falciparum malaria with an asexual P. falciparum parasitemia ≥ 1,000 and ≤ 200,000 parasites/µL at the time of pre-screening with or without other Plasmodium spp. co-infection
  • Axillary temperature ≥ 37.5 ºC or oral temperature ≥ 38.0 ºC or tympanic/rectal temperature ≥ 38.5 ºC; or history of fever during the previous 24 hours (at least documented verbally)
  • Negative pregnancy test for patients of childbearing potential
  • Signed informed consent was obtained before any assessment is performed; for minors, signed informed consent was obtained from parent/legal guardian. If the parent/legal guardian was unable to read and write, then a witnessed consent according to local ethical standards was permitted. Patients who were capable of providing assent, must have provided it along with parent/legal guardian consent or as per local ethical standards
  • The patient and/or their parent/legal guardian was able to understand and comply with protocol requirements, instructions and protocol-stated restrictions and was likely to complete the study as planned

Ki nem vehet részt

  • Concurrent febrile illnesses (e.g., typhoid fever, known or suspected dengue fever, known COVID19)
  • Repeated vomiting (defined as > 3 times in the 24 hours prior to start of screening) or severe diarrhea (defined as > 3 watery stools in the 24 hours prior to start of screening)
  • Prior antimalarial therapy or antibiotics with antimalarial activity within minimum of their five plasma half-lives (or within 4 weeks of screening if half-life was unknown)
  • Any surgical or medical condition which might have significantly altered the absorption, distribution, metabolism, or excretion of drugs (e.g., Human immunodeficiency virus (HIV) patients on antiretroviral therapy (ART) or tuberculosis (TB) patients on treatment), or which may have jeopardized the patient in case of participation in the study
  • Anemia (hemoglobin level <7 g/dL)
  • Any of the following:; Aspartate Aminotransferase/ Alanine Aminotransferase (AST/ALT) > 3 x the upper limit of normal (ULN), regardless of the level of total bilirubin; Total bilirubin > 3 x ULN; Resting QT interval corrected by Fridericia's formula (QTcF) > 450 ms at screening
  • History or family history of long QT syndrome or sudden cardiac death, or any other clinical condition known to prolong the QTc interval, such as history of symptomatic cardiac arrhythmias, clinically relevant bradycardia or severe heart disease
  • Severe malnutrition. For patients ≥ 12 years: body mass index (BMI) < 16.0. For children < 12 years: less than 70% of median normalized WHO reference weight or very low mid-upper arm circumference (MUAC < 115 mm)
  • Signs and symptoms of severe malaria according to WHO 2015 (World Health Organization)
  • Clinically relevant abnormalities of electrolyte balance which required correction, e.g., hypokalemia, hypocalcemia or hypomagnesemia
  • Pregnant or nursing (lactating) patients

Hol van ez a vizsgálat?

12 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study aimed to confirm the efficacy, safety and tolerability of KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF), when administered once daily for three days in adults and children ≥ 10 kg of body weight suffering from uncomplicated P. falciparum malaria (with or without other Plasmodium spp. co-infection).

A teljes eredeti leírásKevesebb

In the extension phase, the safety, tolerability and efficacy of repeated treatment with KLU156 was assessed for a maximum of approximately 18 months in patients who did not experience early treatment failure (ETF), who did not experience any study treatment-related SAE (Serious Adverse Event) previously and who gave informed consent to participate in the Extension phase.

A vizsgálat 4 csoportja

  • KLU156A vizsgált kezelés

    KLU156 once daily (QD) for 3 days under fed conditions (light meal).

  • CoartemMár használt kezelés, összehasonlításként

    Coartem twice a day (BID) for 3 days under fed conditions.

  • KLU156 (Participants with <10 kg Body Weight)A vizsgált kezelés

    KLU156 once daily (QD) for 3 days under fed conditions (light meal).

    Kezelés: KLU156

  • Coartem (Participants with <10 kg Body Weight)Már használt kezelés, összehasonlításként

    Coartem twice a day (BID) for 3 days under fed conditions.

    Kezelés: Coartem

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Open-label, Multicenter Study to Compare Efficacy, Safety and Tolerability of KLU156 With Coartem® in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Adults and Children Followed by an Extension Phase With Repeated KLU156 Treatment
Publikációk
A regiszteradat frissítve
2026. november 4.